Biological Dynamics gets FDA breakthrough device status for Exo-PDAC assay
Exo-PDAC is the liquid biopsy assay developed to facilitate early detection of the pancreatic ductal adenocarcinoma disease, which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Oct 21
Exo-PDAC is the liquid biopsy assay developed to facilitate early detection of the pancreatic ductal adenocarcinoma disease, which…
20 Oct 21
The test is designed to enhance the access to TB testing in regions with high burden of the…
19 Oct 21
By leveraging Natera’s core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology, the Prospera test enables to detect allograft…
19 Oct 21
The EUA status allows to conduct Covid-19 tests using saliva samples collected by the Spectrum Solutions’ SpectrumDNA SDNA-1000…
18 Oct 21
As part of the development and distribution agreement, the two companies will focus on the development of an…
18 Oct 21
The deal will allow Hologic to add laparoscopic vessel sealing, dividing and dissecting devices to its portfolio, in…
18 Oct 21
The funds will be used for the development, validation, manufacturing and scaling of 12 new rapid diagnostic tests…
18 Oct 21
The rapid microfluidic immunofluorescence assay will facilitate the simultaneous identification of SARS-CoV-2, Influenza A, and Influenza B viral…
18 Oct 21
The new plus version of the test provides a third gene target for SARS-CoV-2 detection to meet the…
12 Oct 21
By using the Quanterix HD-X immunoassay system, the blood-based assay will measure the pTau-181 concentration in human serum…